Clinical Trial Update: A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study investigating CM355 in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CM355

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Hematoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING